Carl D. Regillo, MD
Show Description +
Dr. Regillo summarizes findings from the phase 2 DAVIO2 study of EYP-1901 (EyePoint Pharmaceuticals) for the treatment of wet AMD, sharing 12-month end-of-study data.
Posted: 10/28/2024
Carl D. Regillo, MD
Dr. Regillo summarizes findings from the phase 2 DAVIO2 study of EYP-1901 (EyePoint Pharmaceuticals) for the treatment of wet AMD, sharing 12-month end-of-study data.
Posted: 10/28/2024
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2024.
Please log in to leave a comment.